372 related articles for article (PubMed ID: 21130112)
1. The Polypill in the prevention of cardiovascular disease.
Wald DS; Wald NJ
Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
[No Abstract] [Full Text] [Related]
2. [The polypill: not an effective strategy for reduction of cardiovascular disease].
Westerweel PE; van Wijk JP; Verhaar MC
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
[TBL] [Abstract][Full Text] [Related]
3. [The polypill: optimal strategy for reduction of cardiovascular disease].
Nathoe HM; Doevendans PA
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
[TBL] [Abstract][Full Text] [Related]
4. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
Chao J; Bansilal S
Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
[No Abstract] [Full Text] [Related]
5. A single pill for prevention?
Harv Heart Lett; 2009 Jul; 19(11):6. PubMed ID: 19927382
[No Abstract] [Full Text] [Related]
6. Polypill in cardiovascular disease: has it's time come?
Kuppuswamy V; Choo WK; Gupta S
Indian Heart J; 2009; 61(4):322-7. PubMed ID: 20635733
[No Abstract] [Full Text] [Related]
7. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
Joshi SR
J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
[No Abstract] [Full Text] [Related]
8. Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians.
Viera AJ; Sheridan SL; Edwards T; Soliman EZ; Harris R; Furberg CD
Prev Med; 2011 Jan; 52(1):10-5. PubMed ID: 20933538
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?].
Scheen AJ; Lefèbvre PJ; Kulbertus H
Rev Med Liege; 2003 Sep; 58(9):527-33. PubMed ID: 14626644
[TBL] [Abstract][Full Text] [Related]
10. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
11. The polypill to prevent cardiovascular disease: physicians' perspectives.
Viera AJ
Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
[TBL] [Abstract][Full Text] [Related]
12. Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.
Green LW
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S4-8; discussion S9. PubMed ID: 16052194
[TBL] [Abstract][Full Text] [Related]
13. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
14. The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence.
Webster R; Grobbee D; Rodgers A
Eur J Prev Cardiol; 2020 Mar; 27(4):437-440. PubMed ID: 31446790
[No Abstract] [Full Text] [Related]
15. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
Ruiz J; Egli M
Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy to prevent cardiovascular disease: slow progress.
Smith R; McCready T; Yusuf S
JAMA; 2013 Apr; 309(15):1595-6. PubMed ID: 23529576
[No Abstract] [Full Text] [Related]
17. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
18. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
19. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
20. Fixed dose combination therapy and CVD protection: "a need of the hour".
Chopra HK
Indian Heart J; 2009; 61(4):316-21. PubMed ID: 20635732
[No Abstract] [Full Text] [Related]
[Next] [New Search]
